The authors would like to acknowledge the Duke Cancer Institute for providing support for this study. Technical editing was provided by Dr. Donald Kirkendall, LLS, through the Center for Learning Health Care at the Duke Clinical Research Institute.
Dr. Kamal has disclosed that he receives consulting fees from Pfizer, Inc. and INSYS Therapeutics, and grant support from AHRQ, Michigan Oncology Quality Consortium, Retirement Research Foundation, California HealthCare Foundation, and Cambia Healthcare Foundation. Dr. Zhang has disclosed that he receives research support from Janssen Research & Development. The remaining authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.
Schnipper LE, Smith TJ, Raghavan D et al.. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol 2012;30:1715–2724.
Theriault RL, Carlson RW, Allred C et al.. Breast cancer, version 3.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2013;11:753–760; quiz 761.
Zagouri F, Liakou P, Bartsch R et al.. Discrepancies between ESMO and NCCN breast cancer guidelines: an appraisal. Breast 2015;24:513–523.
Barry MC, Thornton F, Murphy M et al.. The value of metastatic screening in early primary breast cancer. Ir J Med Sci 1999;168:248–250.
Houssami N, Turner R, Macaskill P et al.. An individual person data meta-analysis of preoperative magnetic resonance imaging and breast cancer recurrence. J Clin Oncol 2014;32:392–401.
Puglisi F, Follador A, Minisini AM et al.. Baseline staging tests after a new diagnosis of breast cancer: further evidence of their limited indications. Ann Oncol 2005;16:263–266.
Norum J, Andreassen T. Screening for metastatic disease in newly diagnosed breast cancer patients. What is cost-effective? Anticancer Res 2000;20:2193–2196.
Fuster D, Duch J, Paredes P et al.. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol 2008;26:4746–4751.
Wahl RL, Siegel BA, Coleman RE et al.. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. J Clin Oncol 2004;22:277–285.
Crivello ML, Ruth K, Sigurdson ER et al.. Advanced imaging modalities in early stage breast cancer: preoperative use in the United States Medicare population. Ann Surg Oncol 2013;20:102–110.
Simos D, Hutton B, Clemons M. Are physicians choosing wisely when imaging for distant metastases in women with operable breast cancer? [published online ahead of print November 12, 2014]. J Oncol Pract, pii: JOP.2014.000125.
Simos D, Catley C, vanWalraven C et al.. Are physicians “choosing wisely” when imaging for distant metastases in women with early stage (1 or 2) breast cancer? A population study [abstract]. Presented at the 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9–13, 2014; San Antonio, TX. Abstract P1-10-01.
- Search Google Scholar
- Export Citation
. Are physicians “choosing wisely” when imaging for distant metastases in women with early stage (1 or 2) breast cancer? A population study [abstract]. Simos D Catley C vanWalraven C Presented at the 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9–13, 2014; San Antonio, TX. Abstract P1-10-01.
Hahn EH, Tang T, Lee JS et al.. Use of imaging for staging of early breast cancer in two integrated health care systems [abstract]. J Clin Oncol 2014;32(Suppl):Abstract 184.
Simos D, Hutton B, Graham ID et al.. Imaging for metastatic disease in patients with newly diagnosed breast cancer: are doctor's perceptions in keeping with the guidelines? J Eval Clin Pract 2015;21:67–73.
Simos D, Hutton B, Graham ID et al.. Patient perceptions and expectations regarding imaging for metastatic disease in early stage breast cancer. Springerplus 2014;3:176.
Ryoo JJ, Ordin DL, Antonio AL et al.. Patient preference and contraindications in measuring quality of care: what do administrative data miss? J Clin Oncol 2013;31:2716–2723.